“The results of our validation study of Stockholm3 further support its accuracy and generalizability in early detection of significant prostate cancer. The study has provided further support for the Martini Klinik in implementing Stockholm3 in clinical practice,” says Professor Derya Tilki, MD and Principal Investigator of the study.

The Martini Klinik evaluated the performance of both Stockholm3 and the Rotterdam prostate cancer risk calculator (SWOP) in men that met German standards of care to undergo prostate biopsy based on elevated PSA or abnormal rectal exam. In total, 405 men were included in the evaluation. Stockholm3 had a better area under the curve compared to both the SWOP risk calculator and PSA. Findings show that by using Stockholm3, the number of men that underwent benign or Grade Group 1 prostate biopsies could be reduced by 52 percent, while, at the same time, detecting 92% of Grade Group ≥2 prostate cancers compared to using PSA ≥3 ng/ml [1]

“The external and independent validation of Stockholm3 by the Martini Klinik further supports the implementation of Stockholm3 as standard of care in prostate cancer diagnostics. This and other studies show that the number of unnecessary biopsies can be reduced and that the number of aggressive cases detected at an early stage can be increased, when the cancer is still possible to treat and cure,” says Martin Steinberg, Executive Chairman of A3P Biomedical.

1. Tilki, D., Rejek, N., Nohe, F., Haese, A., Graefen, M., & Thederan, I. (2024). External Validation of Stockholm3 in a Retrospective German Clinical Cohort. European urology focus, S2405-4569(24)00129-9. Advance online publication. https://doi.org/10.1016/j.euf.2024.07.009